Press releases

LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans

October 16th 2017

VALBIOTIS announces the efficacy of LIPIDRIVE® is confirmed in three preclinical models and the recruitment for Phase I/II, first study in humans, is being finalized.

Read more

consolidated results for the first half of 2017

September 29th 2017

VALBIOTIS consolidated results for the first half of 2017 and major progress in clinical studies.

Read more

International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board

September 20th 2017

VALBIOTIS announced the arrival of Jean ZETLAOUI on Valbiotis’ Supervisory Board.

Read more

VALBIOTIS: Pascal SIRVENT appointed Director of Discovery and Preclinical Research

September 14th 2017

VALBIOTIS announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017.

Read more